PRECLINICAL REGULATORY CLINICAL

Your drug's
journey
begins here.

Enlisting an integrated suite of
cutting-edge preclinical tools
to direct clinical development.

Learn More
 
 
April 5 - 9, 2014
San Diego, CA
Omni Hotel
TD2 NEWS
TGEN NEWS
  • MPI and TD2 Join in Strategic Collaboration to Provide Drug Developers a...READ MORE >
  • Nuvilex Retains TD2 to Conduct Preclinical and Clinical Studies...READ MORE >
  • Forma Therapeutics makes deal with Celgene worth $600M
    <...READ MORE >
  • Dr. Von Hoff's research led to development of numerous therapeut...READ MORE >

Translational Drug Development (TD2) attracts Dallas partner

ORIX USA brings investment dollars that will enable TD2 to expand; help grow Arizona’s biomedical economy

SCOTTSDALE, Ariz., and DALLAS, Texas — Dec.18th, 2013 — ORIX USA Health and Life Sciences has completed an investment into Translational Drug Development (TD2) through the purchase of equity from the Translational Genomics Research Institute (TGen).

TGen will remain a significant minority equity holder in TD2, which has been a for-profit subsidiary of the non-profit TGen.

ORIX USA, a Dallas-based diversified financial conglomerate with nearly $ 5 billion in assets and $30 billion of assets under management, will provide the capital needed to enable TD2 to expand its capabilities to assist pharmaceutical companies in the development of new drugs based on the specific molecular profile of individual cancer patients.   

Under the leadership of President and CEO Dr. Stephen Gately, TD2 has managed and designed hundreds of preclinical and clinical engagements that have measurably improved the drug discovery process in one of humans’ most complex disease areas, cancer. TD2’s unique approach to patient identification, high throughput computational chemistry, and advanced genomic and diagnostic data analysis, gives the company a distinct and sustainable scientific advantage towards accelerate drug discovery in the fields of oncology and rare disease.

ORIX USA and TD2 will establish a unique and capital-efficient drug development model that leverages TD2’s broad capabilities and oncology expertise with ORIX’s international financial and operational resources.

Click here for full press release